The UK Life Sciences Industrial Strategy should be required reading for every healthcare leader in the UK. It makes clear that the NHS must be an active participant with industry in delivering the shared objective of outstanding patient outcomes.
The ABPI has produced this sourcebook to support pharmaceutical companies in working successfully and collaboratively with patients and patient organizations.
Pharmaceutical companies are doing everything in their power to avoid disruption to the supply of medicines in all Brexit scenarios. This includes increasing stocks of medicine in the UK, changing supply routes, transferring medicine licenses and duplicating testing in the EU.
The UK has robust measures in place to ensure that medicines and vaccines are both clinically and cost effective before they can be used in the NHS.
Illness never sleeps. It grows, mutates and causes pain and suffering. Disease never takes a break, so neither do we. Because people fighting disease deserve the best chance to live. We won’t rest until people around the world see a brighter tomorrow.
Millions of people wouldn't be here today if it wasn't for life-changing science. And many more wouldn't be living the lives they do.
18 July 2019
The Home Office have released their annual statistics on animals used in research in Great Britain. It shows 3.52 million procedures were carried out in 2018, a 7% decrease on the 2017 numbers.
09 July 2019
The Government has announced further details for how they will support pharmaceutical companies’ investments in the development of drugs that will treat AMR infections.
03 July 2019
The ABPI's Chief Executive, Mike Thompson, has announced that he is due to retire at the end of 2019.
28 June 2019
New figures published today by the ABPI show that the pharmaceutical industry continues to invest significantly in UK research and development, working with healthcare professionals and organisations to improve care for NHS patients.
20 June 2019
Jamie Harvey from AstraZeneca is one of around 40,000 people employed in medicines manufacturing in the UK. He gives his perspective on what it’s like to be an apprentice in the sector.
05 June 2019
Dr Richard Torbett provides an ABPI view on medicines pricing in the UK and the current situation between NHS England and Vertex on access to Orkambi for Cystic Fibrosis patients